Hematopoietic stem cell (HSC) defects can cause repopulating impairment leading to hematologic diseases. To target HSC deficiency in a disease setting, we exploited the repopulating defect of Fanconi anemia (FA) HSCs to conduct an in vivo short hairpin RNA (shRNA) screen. We exposed Fancd2 À/À HSCs to a lentiviral shRNA library targeting 947 genes. We found enrichment of shRNAs targeting genes involved in the PPARg pathway that has not been linked to HSC homeostasis. PPARg inhibition by shRNA or chemical compounds significantly improves the repopulating ability of Fancd2 À/À HSCs. Conversely, activation of PPARg in wild-type HSCs impaired hematopoietic repopulation. In mouse HSCs and patient-derived lymphoblasts, PPARg activation is manifested in upregulating the p53 target p21. PPARg and co-activators are upregulated in total bone marrow and stem/progenitor cells from FA patients. Collectively, this work illustrates the utility of RNAi technology coupled with HSC transplantation for the discovery of novel genes and pathways involved in stress hematopoiesis.
INTRODUCTION
Hematopoietic stem cells (HSCs) are a distinct population of multipotent cells that can self-renew and differentiate into various types of blood cells and thus are responsible for maintenance and homeostasis of a healthy hematopoietic system (Morrison et al., 1995; Orford and Scadden, 2008; Orkin and Zon, 2008) . HSCs are exposed daily to internal and external stresses which in turn lead to DNA damage. Accumulation of DNA damage in hematopoietic stem and progenitor cells (HSPCs) during the cell's life span is a factor of hematopoietic system aging and degeneration, and likely contributes to transformation and cancer development (Rossi et al., 2008) . Accelerated bone marrow (BM) degeneration leading to BM failure and high risks of leukemia development is frequently observed in diseases with a deficiency in DNA repair pathways such as Fanconi anemia (FA) (Taniguchi and D'Andrea, 2006) .
FA is an inherited disease caused by mutations in any of 17 already identified FA DNA repair pathway genes (FANCA-S) (Kottemann and Smogorzewska, 2013; Sawyer et al., 2015) . FA proteins have been mainly studied for their role in genomic DNA repair and genome integrity. Upon DNA damage, eight of the FA proteins (FANCA, -B, -C, -E, -F, -G, -L, and -M) interact to form the FA core complex responsible for FANCD2 and FANCI activation by mono-ubiquitination (Kottemann and Smogorzewska, 2013) . FANCD2 activation is essential for genome integrity maintenance upon double DNA strand break or interstrand crosslinking by favoring the homologous recombination (HR) DNA repair pathway.
BM failure and leukemia at a young age are the hallmarks of human FA patients, which made the study of FA of high interest for understanding the biology of HSC defect and malignant transformation. Mouse models have been developed for several FA genes (Parmar et al., 2009) . Despite the mild phenotypes and absence of BM failure in a steadystate condition, FA mouse models present hypersensitivity to DNA-damaging agents, oxidative stress and a deficiency of HSC repopulation abilities (Parmar et al., 2009 ). Studies of these mouse models have allowed advances in understanding factors and pathways involved in HSC normal functions and BM failure. For example, the study of FANCD2 interaction partners has demonstrated the importance of FOXO3a/FANCD2 interaction in HSC maintenance and resistance against oxidative stress . Recently, a study emphasizing the relationship between DNA damage and HSC impairment has shown that repeated stresses led to the accumulation of DNA damage and acceleration of functional impairment in FA HSCs (Walter et al., 2015) . Despite this accumulation of knowledge about BM failure, potent treatment for FA patients is still needed. Unbiased genomic approaches by short hairpin RNA (shRNA) screens have been successfully used to discover new mechanisms in different pathologies (Mohr et al., 2014) , and can be conducted at a stem cell level (Hope et al., 2010; Wang et al., 2012) . Using such a strategy, several tumor suppressors and checkpoint factors have been highlighted, such as p53 and p21. Interestingly, several of these proteins have also been implicated in tissue aging and stem cell functions.
In this study, we took advantage of the well-established defective repopulation of FA HSCs and carried out an in vivo shRNA screening in the Fancd2 mouse model to identify genes whose inhibition would improve HSC functions during replicative stress. We demonstrated that deregulated Pparg activity is a limiting factor for HSC Figure 1A ). To maximize the efficiency of the screening, we used Fancd2-deficient mice as they have the strongest phenotypes (Parmar et al., 2009) and HSPC deficiency compared with other FA mice used in our laboratory (Figures S1A and S1B). The shRNA library used in this screen was derived from previously published studies (Bric et al., 2009; Wang et al., 2012) . The shRNA lentiviral vector used for the screening expressed a recombinant GFP protein, allowing a fast evaluation of transduction efficiency of the LSKs and the sorting of shRNA-expressing donor cells after transplantation (Figures S2A and S2B) . Pooled LSKs (CD45.2) from WT or Fancd2 À/À mice were transduced in vitro with a similar transduction efficiency of 70%-75% in both genotypes ( Figure S2 ) and then transplanted ( Figure 1A ) into lethally irradiated recipients (CD45.1). A decreased blood donor chimerism (Figure 1B) and different blood parameters ( Figure 1C) Figure S2 ). We found that the majority of the shRNAs were still present in the sorted cells of both genotypes (Figure 1D ) when compared with the virus-producing cells, indicating no random loss of shRNAs during the experiment.
The enrichment analysis conducted using ShRNAseq Pipeline (Sims et al., 2011) indicated the selection or loss of shRNAs in recipient mice of Fancd2 À/À cells compared with the recipient of WTcells (Table S1 and Figure 1E ). Significantly, we found enrichment of three targeted genes of the transforming growth factor b (TGF-b) pathway, Fos (Zhang et al., 1998) , Elf (Chang et al., 2000) , and Klf10 (Spittau and Krieglstein, 2012) (Figures S3B and S3C) , and four targeted genes of the PPARg pathway, Fos (Wan et al., 2007) , Ncoa4 (Heinlein et al., 1999) , Pparg, and Zfml (Meruvu et al., 2011) (Figures 1E and 1F ; Table S1 ).
Specific shRNA Knockdown of Identified Genes Improves Repopulation Activity of Fancd2 À/À HSCs
To validate the target genes identified by our screening strategy, we transduced WT and Fancd2 À/À LSKs with shRNAs targeting the specific genes identified in our in vivo screen. We decided to focus on the Pparg-related genes, because the pathway is the most enriched in our screen and because PPARg is already a therapeutic target that could be interesting for clinical use (Schmidt et al., 2010 Figure S3E ). We also confirmed the deleterious effect of Klf10 knockdown (Figure 2B and Table S1 ). As a non-specific control, we used a non-enriched shRNA targeting the nuclear receptor Nr2c1 and found no significant difference of GFP + proportion 16 weeks after transplantation ( Figure 2C ). Furthermore, we performed serial BM transplantation assays and confirmed the increased repopulation activity of shPparg-transduced Fancd2 À/À HSCs in secondary and tertiary recipient mice ( Figure 2D ). Interestingly, after the third round of transplantation we also found an increase of GFP + proportion in shPparg-transduced WT blood donor-derived cells compared with scramble shRNA-transduced cells ( Figure 2D ). This result indicates a possible benefit of Pparg knockdown during repeated replicative (C) LSKs isolated from Fancd2 +/+ or Fancd2 À/À mice (n = 5 donors/group, two independent experiments) were transduced with shRNA targeting Pparg or scrambled shRNA control. The transduction efficiency was 25%-33% before transplantation and was normalized to 1. Transduced cells, along with untransduced cells, were transplanted into lethally irradiated Boy/J (n = 8 mice/group, two independent experiments). The graph shows relative changes in GFP + proportion among donor-derived Lin À BM cells (CD45.2) at 16 weeks after transplantation.
(legend continued on next page) stress on normal HSCs. Together, these results confirmed that specific knockdown of the targeted genes identified in the in vivo shRNA screen has an impact on the repopulation activity of Fancd2 À/À HSCs, and that PPARg could be a potential target for improvement of repopulation capacity and function of Fancd2 À/À HSCs.
PPARg Activation Impaired Function of Both WT and Fancd2-Deficient HSPCs Next, we evaluated the effect of PPARg inhibition on the function of HSPCs in vitro and in vivo. As expected, we observed with the shScramble a decrease in colony numbers for Fancd2 À/À LSKs compared with WT LSKs after the first or second passage ( Figure 3A ). Targeting WT LSKs by shPparg did not change the colony number during the first or second passage ( Figure 3A ). In contrast, Pparg knockdown in Fancd2 À/À LSKs led to a significant increase in colony number compared with shScramble in both the first and second round of culture. The Fancd2 À/À LSK-derived colonies remained significantly lower than those of WT LSKs (Figure 3A) . To confirm this result and to evaluate a possible pharmacological targeting of PPARg activity in HSPCs, we used the well-characterized PPARg antagonist T0070907 (Lee et al., 2002) and agonist troglitazone (Lee and Olefsky, 1995) . Inhibition of PPARg activity did not affect the colony number of WT LSK cells at 20 or 100 nM ( Figure 3B ). However, treatment by T0070907 significantly increased the colony-forming ability of Fancd2 À/À LSKs, indicating a partial rescue when compared with WT LSKs. Significantly, we found a dose-dependent decrease in colonies formed by WT LSKs treated with the PPARg agonist, indicating that the activation of PPARg is sufficient to inhibit the colony-forming capacity of WT LSKs in vitro. Interestingly, troglitazone treatment had no effect on Fancd2 À/À colony number, indicating that Pparg activation is probably already at maximum in these cells. We next evaluated the consequence of Pparg inhibition on HSC function in vivo. We transduced the WT and is the same in all the conditions tested ( Figure 3F ). Altogether, these data indicate a deleterious effect of PPARg activation on HSC function and suggest the potential benefit of PPARg inhibition on Fancd2 À/À HSCs.
Elevated Expression of PPARg Co-activators and Target Genes in Fancd2 À/À HSPCs
To determine the mechanism underlying deregulated PPARg activity in Fancd2-deficient HSPCs, we evaluated the expression of PPARg co-activators and target genes in donor-derived LSK cells 2 weeks after transplantation. At that time, the HSPCs were under a high proliferative and inflammatory stress because of the need to reconstitute the damaged hematopoietic system (Roy et al., 2012) . Surprisingly, we observed no difference in the expression for the two Pparg variant mRNAs in sorted CD45.2 + WT and Fancd2 À/À LSKs from transplanted mice ( Figure 4A ). Since it has been described that Pparg expression is not always a good indicator of activity, we evaluated the expression of the PPARg co-activators Ncoa4 (Heinlein et al., 1999) , Ppargc1a (Puigserver et al., 1998) , and Ppargc1b (Lin et al., 2002) . We observed significantly increased expression of Ppargc1a and Ncoa4 in donor-derived Fancd2 À/À LSKs at 2 weeks post transplantation ( Figure 4A ). Interestingly, Ncoa4 was one of the hits in our shRNA screening (Figure 2B) . We also analyzed our microarray data obtained with freshly isolated phenotypic HSCs (CD150 + CD48 À LSK; F F F F F F F a a a a a a a a a a a a a a a a a a n n n n n n n n n n n n n n n n n n n c c c c c c c c c c c c c c c c c c c d d d d d d d d d d d d d d d 
E). (F) LSKs from 8-to 12-week-old Fancd2
À/À or Fancd2 +/+ mice (n = 4 mice/genotype) were treated for 48 hr with 1 mM troglitazone, and 2,000 live cells were transplanted into lethally irradiated Boy/J mice along with CD45.1 competitor BM recipient cells. The bar graph depicts the blood chimerism (CD45.2 + cells) of recipient mice 10 weeks after transplantation.
(legend continued on next page) SLAM) from WT and Fancd2 À/À mice (GEO: GSE64215). Several Pparg target genes are deregulated in the Fancd2 À/À SLAM population ( Figure 4B ). We did not observe in this microarray the deregulation of Ncoa4 or Ppargc1a, suggesting the possible requirement for higher stress conditions to upregulate their expression. As previously reported in FA-deficient cells (Barroca et al., 2012; Ceccaldi et al., 2012) , we found upregulation of Cdkn1a (p21) in Fancd2 À/À SLAM cells in the Slam microarray ( Figure 4B ). Moreover, shRNA targeting Cdkn1a was enriched in our shRNA screen ( Figure 1 and Table S1 ). (Figures 4C and 4D ). We treated WT LSK cells with troglitazone and found that activation of Pparg increased the expression of Cdkn1a and Ncoa4 ( Figure 4E ). In accordance with the colony assay, we were unable to find a difference in Cdkn1a and Ncoa4 expression after treatment in Fancd2 À/À LSKs. These data support the notion that PPARg regulates Cdkn1a and Ncoa4 expression in HSPCs. The observation that activation of PPARg by troglitazone increased the expression of Cdkn1a in WT LSKs prompted us to ask whether activation of PPARg inhibited HSPC repopulation capacity. To this end, we treated WT and Fancd2
À/À
LSKs ex vivo with troglitazone and evaluated the hematopoietic repopulating capacity of the treated HSPCs using a BM transplantation assay. At 10 weeks after transplantation, troglitazone-treated WT HSPCs were less efficient in repopulating the irradiated recipients than untreated WT LSKs ( Figure 4F ). Interestingly, activation of PPARg in Fancd2 À/À HSCs did not further impair the repopulation activity. No difference in apoptosis was observed in LSKs treated with troglitazone during 48 hr (data not shown). Thus, the impaired repopulation does not seem to be linked to increased cell death before transplantation. To validate in vivo our in vitro data, we transplanted lethally irradiated mice with WT or Fancd2 À/À LSKs transduced by shScramble or shPparg, along with recipient competitor LSKs. As observed in vitro, inactivation of PPARg by shRNA led to a decreased expression of Cdkn1a and Ncoa4 at 2 weeks post transplantation ( Figure 4G ). We further confirmed the beneficial role of PPARg inhibition on Fancd2
HSPCs by treating transplanted mice with the antagonist T0070907 during the first 4 weeks after irradiation, when the donor cells are subjected to a high level of replicative stress due to rigorous BM repopulation. As observed with Pparg shRNA knockdown, in vivo inhibition of PPARg activity by T0070907 led to a partial rescue of Fancd2
HSC repopulation capacity ( Figure 4H ). Long-term evaluation of transplanted mice showed an extended life span of mice receiving shPparg-transduced Fancd2
LSKs compared with mice receiving shScramble-transduced Fancd2 À/À LSKs ( Figure S3F ). Notably, after 1 year no sign of leukemia was observed as depicted by the white blood cell count at 50 weeks ( Figure S3G ). Altogether, these data indicate that HSPCs are able to respond to aberrant PPARg activity and that PPARg activation under replicative stress impairs FA HSPC function, likely through upregulating Cdkn1a expression.
Upregulated PPARg and Its Co-activators in FA Patient-Derived Cell Lines and Primary FA Patient Samples
We next evaluated whether our findings in the mouse model were extendable to humans. We first compared the expression of PPARg, NCOA4, CDKN1a, and PPRgC1a in human FANCD2-deficient lymphoblastic cell lines genetically complemented (PD20 WT ) or not (PD20 Vect ) by WT human FANCD2 cDNA. We observed a significant increase in the expression of NCOA4, CDKN1a, and PPARgC1a in FANCD2-deficient cells compared with the complemented cells ( Figure 5A ). Since antioxidant treatment is able to ameliorate PD20 FA phenotypes (Li et al., 2012 (Li et al., , 2014 Ponte et al., 2012) , we decided to evaluate the expression of the PPARg-related genes in response to treatment with hydrogen peroxide (H 2 O 2 ). Oxidative stress increased expression of CDKN1a and PPARgC1a ( Figure 5B ). Interestingly, treatment with H 2 O 2 elevated the expression of NCOA4, indicating a link between oxidative stress and this PPARg co-activator. However, H 2 O 2 treatment did not increase the expression of PPARg in PD20 WT cells (Fig- ure 5B). It is possible that oxidative stress affects the activity of PPARg, not its gene expression. To test this notion, we inhibited PPARg activity using T0070907 in PD20 WT cells (G) Real-time qPCR measurement in sorted LSKs 2 weeks after transplantation of LSKs from 8-to 12-week-old Fancd2 À/À or Fancd2 +/+ mice transduced with shScramble or shPparg into lethally irradiated Boy/J recipient mice (n = 4 mice/group). (H) LSKs were sorted from 8 to 12 weeks old Fancd2 À/À or Fancd2 +/+ mice (n = 4 mice/genotype), and 2,000 sorted LSKs (CD45.2) were transplanted into lethally irradiated Boy/J mice along with 2,000 competitor LSKs (CD45.1). Mice were injected intraperitoneally every other day with T0070907 (5 mg/kg) or control vehicle (DMSO) (n = 4 mice/group) during the first 4 weeks after transplantation. The bar graph depicts the blood chimerism (CD45.2 + cells) of recipient mice 16 weeks after transplantation. WT, wild-type. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
exposed to H 2 O 2. Inhibition of PPARg significantly reduced the expression of CDKN1a upon H 2 O 2 treatment (Figure 5C ), indicating that PPARg participates in the regulation of this gene in response to oxidative stress. PPARg inhibition did not change the expression of NCOA4 and PPARgC1a ( Figure 5C ).
To substantiate the human relevance further, we analyzed the published transcriptome data derived from + cells from normal (n = 8) or FA patients (n = 10). Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant. BM cells of a large cohort of FA patients (GEO: GSE16334) (Vanderwerf et al., 2009) for PPARg-related genes. Interestingly, we found significantly increased expression of CDKN1a and NCOA4 in FA patients ( Figure 5D ). While we did not find upregulation of PPARg ( Figure 5E ) and PPARgC1a (data not shown), we found upregulation of RXRa ( Figure 5D ), a gene encoding another co-activator of PPARg (Mangelsdorf and Evans, 1995) . Furthermore, we observed by real-time qPCR a significant elevation in the expression of PPARg in BM HSPCs (CD34 + ) isolated from a small cohort of FA patients compared with the samples from healthy donors ( Figure 5F ). Together, these data suggest that consistent with its role in Fancd2 À/À HSPCs, deregulated PPARg activity may contribute to BM pathology in FA patients.
DISCUSSION
The current study provides several pieces of evidence that abnormal Pparg activation in HSCs leads to HSC function impairment under replicative stress. (1) shRNA against Pparg and Pparg-related genes were enriched in Fancd2-deficient HSPCs undergoing hematopoietic repopulation.
(2) Specific knockdown of Pparg improved the repopulation capacity of Fancd2-deficient HSCs. (3) Genetic or pharmacological inhibition of Pparg decreased expression of Cdkna1a in mouse and human FA-deficient cells and improved the repopulation capacity of Fancd2-deficient HSCs. PPARg is a central transcription factor regulating adipocyte differentiation and energy metabolism (Siersbaek et al., 2010) . Interestingly, increased population of adipocytes in the BM has been observed in FA patients and mouse models (Pulliam-Leath et al., 2010) , suggesting a possible dysregulation of PPARg. Moreover, it has been shown that adipocytes are deleterious for HSC self-renewal (Naveiras et al., 2009 ). These observations are in accordance with our current study demonstrating that pharmacological or intrinsic activation of PPARg impaired hematopoietic repopulation of Fancd2-deficient HSCs as well as WT HSCs. In this context, it is noteworthy that our recent study (Amarachintha et al., 2015) with Fanca-and Fancd2-deficient BM mesenchymal stromal cells revealed upregulation of PPARg activity and Ppargc1a expression and adipocyte differentiation in FA, suggesting that hyperactivation of PPARg could be a common feature of FA cells. In accordance with a deleterious effect of PPARg on the hematopoietic system, development of anemia in humans has been shown to be a side effect after the introduction of a PPARg agonist drug on the market (Werner and Travaglini, 2001 ). In addition, FA patients are frequently treated with androgens, which delay BM failure (Dokal, 2003) . Interestingly, androgen and PPARg signaling inhibit each other (Dokal, 2003; Du et al., 2009; Singh et al., 2006) . Thus, the effectiveness of androgen treatment in FA patients may be in part related to PPARg inhibition, although this hypothesis has to be investigated.
Since the p53/p21 axis has been described as an impairment mechanism of FA-deficient HSCs and also plays important roles in other models of HSC aging (Choudhury et al., 2007) , we evaluated the effect of PPARg on CDKN1a expression. We found that inhibition of PPARg downregulated the expression of CDKNA1a in FANCD2-deficient human lymphoblast cell line (PD20) and mouse Fancd2 À/À HSPC (LSK) cells. PPARg interacts and activates p53 to upregulate p21 expression (Han et al., 2003) and can bind directly to the TP53 promoter to increase p53 expression (Bonofiglio et al., 2006) . Interestingly, the levels of the p53 protein are known to be upregulated in FANCD2-deficient PD20 cells and Fancd2 À/À mouse LSK cells (Ceccaldi et al., 2012) . In connection with PPARg and p53 interaction, PPARg activation leads to an increase in cell-cycle arrest and apoptosis in different cancer cell types (Burstein et al., 2003; Mueller et al., 2000; Theocharisa et al., 2003) . In this context, we speculate a possible linkage between PPARg activation and upregulation of p21 through p53 upregulation. Since direct targeting of p53 or p21 is not a safe therapeutic strategy, treatments that modulate the p53/p21 activity might improve HSC functions while maintaining vital tumor-suppressive functions. In supporting this notion, we kept lethally irradiated recipient mice reconstituted with Scramble or shPparg -transduced Fancd2 À/À LSK cells for 1 year without detecting leukemia development. Surprisingly, we did not observe an alteration in PPARg expression in FANCD2-deficient PD20 cells and HSPCs or the published FA patient BM microarray. However, we detected overexpression of PPARg in human FA CD34 + BM cells, suggesting that modulation of PPARg expression might be more important in primitive HSCs. Since PPARg level in either gene expression or total protein is not always a good indicator of its activity, we evaluated the expression of PPARg co-activators. We found significantly increased expression of NCOA4, a known co-activator of PPARg (Heinlein et al., 1999) and a hit in our screen, in mouse Fancd2-deficient LSKs after transplantation and in BM cells of an FA patient. This similarity in the mouse model and human samples suggests a possible deleterious role of PPARg in humans. Nevertheless, no functional assessment has been conducted on human HSPCs in this study, and further studies are needed to confirm the relevance of PPARg signaling in primary human cells and patients.
Little is known about the relationship between NCOA4 and PPARg beyond transcriptional co-activation. In this study, we showed that PPARg regulated the expression of NCOA4 under oxidative or replicative stress. Interestingly, it has been recently reported that inhibition of NCOA4 confers resistance to oxidative stress (Mancias et al., 2014) . We and others have described the hypersensitivity of FA-deficient cells to oxidative stress (Pagano et al., 2012) . Moreover, we have shown that treatment of FA mice with the antioxidant quercetin can ameliorate the FA phenotype (Li et al., 2014) , and a pilot study on the use of quercetin in FA patients is in progress at the Cincinnati Children's Hospital. Thus, it is possible that the upregulation of NCOA4 in FA-deficient cells has a direct impact on PPARg activation and sensitivity to oxidative stress. Another link between PPARg and oxidative stress comes from the direct activation of PPARg by oxidative stress (Polvani et al., 2012) . In fact, oxidative stress is a known inducer of PPARg activity. PPARg is believed to play a protective role against oxidative stress under physiological conditions. The increased levels of reactive oxygen species (ROS) in FA cells could be responsible for an increased and sustained activation of PPARg that could impair HSC functions. In support of this notion, we found that treatment of human cells with H 2 O 2 elevated the expression of the PPARg-related genes such as NCOA4, CDKN1a, and PPARgC1a, and that activation of PPARg in WT murine LSKs impaired their repopulation activities. Finally, we observed an upregulation of PPARgC1a in Fancd2-deficient mouse LSKs as well as in FANCD2-deficient PD20 cells. PPARgC1a can act as co-stimulator of PPARg (Puigserver et al., 1998) , which has an important role in mitochondrial biogenesis (Wu et al., 1999) . Emerging evidence shows that FA deficiency leads to damaged mitochondria (Pagano et al., 2012 (Pagano et al., , 2014 . It is conceivable that when repopulating the BM upon stress, HSCs would have to enter the cell cycle that requires enhanced mitochondrial activity to meet high energy demand, which would increase ROS production. We speculate that because of damaged and less efficient mitochondria, the FA-deficient HSCs need to increase mitochondrial biogenesis to meet energy demand. Therefore, upregulation of PPARgC1a in FA may be due to mitochondrial damages leading to increased accumulation of ROS, which in turn activates PPARg.
In summary, using an in vivo shRNA screen in donor HSCs, we identified a deleterious effect of deregulated Pparg activity on HSC functions. Modulation by pharmaceutical compounds of PPARg signaling is potentially a therapeutic modality in a large proportion of patients with blood diseases, including FA.
EXPERIMENTAL PROCEDURES

Mice
Mice were maintained in a pathogen-free environment in the Cincinnati Children's Hospital Medical Center (CCHMC) mouse housing facility. 
Cell Culture
Sorted LSKs were cultured in Stem Span SFEM medium (STEMCELL Technologies) supplemented with 100 ng/mL murine stem cell factor and 50 ng/mL murine thrombopoietin (Preprotech). The Pparg agonist troglitazone or antagonist T0070907 (Cayman) were added at the initiation of culture at the concentration indicated on the figures. For colony-forming assay, 200 LSKs or 5 3 10 3 MNC BM cells were cultured into cytokines supplemented Methocult3434 medium (STEMCELL). Colonies were counted on day 7 and replated for the second round in the same condition.
shRNA Library and Vector Construction
The shRNA library pool was provided by Dr. Lenhard Rudolph (Max-Planck-Research Institute) (Wang et al., 2012) . Construction details about SFFVDEcoR1-Egfp-shRNA vector use in specific gene silencing are provided in Supplemental Experimental Procedures.
LSK Transduction and In Vivo Screening
A schematic experimental flow of the LSK transduction for shRNA screening is depicted in Figure S1 . In brief, sorted Fancd2 À/À or 
Integrated shRNA Detection and Enrichment Analysis
We adapted the protocol and primers previously described (Sims et al., 2011) (Figure S2 and Supplemental Experimental Procedures) . FASTQ files generated after sequencing of screening were mapped to the shRNA library sequence using the ShAlign Perl program (Sims et al., 2011) . The enrichment score of each shRNA sequence was calculated using the ShRNAseq R package (Sims et al., 2011) .
Real-Time qPCR
Total RNA was isolated from cells in culture or freshly sorted LSKs with the RNeasy plus mini kit (QIAGEN). Reverse transcription of total mRNA was obtained using The High Capacity cDNA kit (Applied Biosystems). qPCR was conducted on an ABI 7900 (Applied Biosystems). Primers for qPCR are listed in Figure S4 .
Statistical Analysis
Student's t test was used for two-group comparison and one-way ANOVA for more than two-group comparison using the Tukey post hoc test to correct for multiple comparisons with GraphPad Prism software. Values of p < 0.05 were considered statistically significant. Results are presented as mean ± SD. Values in the figures are depicted as *p < 0.05, **p < 0.01, and ***p < 0.001. 
SUPPLEMENTAL INFORMATION
